China's National Medical Products Administration approved for marketing today a novel-target innovative drug that was developed and filed simultaneously across jurisdictions, the agency said. Xu Xiaoqiang, director of the Chemical Drugs Office at the NMPA's Drug Registration Department, said the drug was submitted concurrently to China, the United States and Japan and that China approved it first, marking a historic first-in-China filing-and-launch after the drug progressed from original target

China's National Medical Products Administration approved for marketing today a novel-target innovative drug that was developed and filed simultaneously across jurisdictions, the agency said. Xu Xiaoqiang, director of the Chemical Drugs Office at the NMPA's Drug Registration Department, said the drug was submitted concurrently to China, the United States and Japan and that China approved it first, marking a historic first-in-China filing-and-launch after the drug progressed from original target discovery to international multicenter clinical trials and registration.